Therapeutic Area | MeSH |
---|---|
infections | D007239 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
helminthiasis | EFO_1001342 | D006373 | B65-B83 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Niclosamide |
INN | niclosamide |
Description | Niclosamide is a secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections. It has a role as a piscicide, a molluscicide, an antiparasitic agent, an anticoronaviral agent, an anthelminthic drug, an apoptosis inducer and a STAT3 inhibitor. It is a member of monochlorobenzenes, a member of salicylanilides, a C-nitro compound, a secondary carboxamide and a member of benzamides. It is functionally related to a 5-chlorosalicylic acid. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O |
PDB | — |
CAS-ID | 50-65-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1448 |
ChEBI ID | — |
PubChem CID | 4477 |
DrugBank | DB06803 |
UNII ID | 8KK8CQ2K8G (ChemIDplus, GSRS) |